Cytodyn Inc To Host Investment Community Conference Call Transcript
I will now turn the call over to Dr. Nader Pourhassan.
Thank you, Mike, and thank you, everyone, for being on this call. As of about an hour ago, CytoDyn has requested from the FDA to grant CytoDyn an Emergency Use Authorization for leronlimab based on CD10 data for mild-to-moderate COVID-19 population.
With that said, I would like to first discuss the results of our Phase 2 clinical trial, CD10. What is good outcome of a given Phase 2 and what is bad outcome? A best-case scenario for any Phase 2 is to be able to achieve a primary endpoint with a statistically significance value or any secondary endpoints with a statistically significant value.
Now, these items, these endpoints are listed on a Phase 2 because this is a proof of concept, so a sponsor of a drug development can find out which item wants to be the primary endpoint for the Phase 3 that will follow a successful Phase 2. Obviously, safety is very, very important. So a bad outcome would be if there is any problem with the safety that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
